Brian R. de Costa - Concepedia

Author

Brian R. de Costa

National Institutes of Health

Also Known As

Brian R De Costa, Brian R de Costa, Brian R. De Costa, Brian R. de Costa

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Mental Health National Institute on Drug Abuse University of Oklahoma Health Sciences Center

About

Brian R. de Costa is an author at National Institutes of Health specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	38	2.7K
2	Biochemistry	14	15	694
3	Natural Sciences	12	12	589
4	Social Sciences	10	10	994
5	Health Sciences	5	5	406

Brian R. de Costa

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Miles Herkenham, Allison B. Lynn, Brian R. de Costa, Brain Research Cannabis UseNeurophysiologyNeuroanatomyMedicineNeuropharmacology	1991	515
Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism Rae R. Matsumoto, Wayne D. Bowen, Michael A. Tom, European Journal of Pharmacology Molecular PharmacologyAntidystonic EffectsMedicineImmunologyMechanism Of Action	1995	266
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain Richard B. Rothman, Victor Bykov, Brian R. de Costa, Peptides Opioid EpidemicNeurophysiologyAddictionMedicineNeuropeptide Receptor	1990	146
Synthesis and evaluation of optically pure [<sup>3</sup>H]‐(+)‐pentazocine, a highly potent and selective radioligand for σ receptors Brian R. de Costa, Wayne D. Bowen, Susan B. Hellewell, FEBS Letters PharmacotherapyHeterocycle ChemistryExperimental Pharmacologyσ Receptor LigandsPharmaceutical Chemistry	1989	141
Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay Jillian H. Broadbear, S. Stevens Negus, Eduardo R. Butelman, Psychopharmacology Molecular PharmacologyDifferential EffectsBehavioral NeuroscienceAddictionMedicine	1994	138
GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine Richard B. Rothman, Andrea Mele, Audrey A. Reid, Pharmacology Biochemistry and Behavior AddictionMedicineNeurotransmitterPsychopharmacologyNeuropharmacology	1991	127
Two novel σ receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity Kari A. McCracken, Wayne D. Bowen, Brian R. de Costa, European Journal of Pharmacology Molecular PharmacologyAddictionMedicineMechanism Of ActionNeuropharmacology	1999	111
Drug specificity of pharmacological dystonia Rae R. Matsumoto, Mitzi K. Hemstreet, Naline L. Lai, Pharmacology Biochemistry and Behavior Drug SpecificityMedicinePsychotropic MedicationNeuropharmacologyPharmacotherapy	1990	97
Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter Richard B. Rothman, Nigel H. Grieg, Andrew Kim, Pharmacology Biochemistry and Behavior Health SciencesNeurophysiologyDopamine TransporterPhysiologyMotor System	1992	83
Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting σ1 receptors produce anti-cocaine effects in mice Rae R. Matsumoto, Kari A. McCracken, Michele J Friedman, European Journal of Pharmacology Molecular PharmacologyDrug TargetAntisense OligodeoxynucleotideMedicineNatural Sciences	2001	73

Page 1